2月6日，东方金诚国际信用评估有限公司(以下简称"东方金诚")发布《东方金诚国际信用评估有限公司 关于博瑞生物医药(苏州)股份有限公司2025年度业绩下滑的关注公告》(以下简称《公告》)称，上述事 项发生后，东方金诚通过向公司邮件询问、查询公开资料等方式了解到，公司业绩下滑主要系：受流感 趋势变化、竞争格局变化、客户阶段性商业需求波动等影响，使得当期营业收入及产品毛利额减少，以 及在建工程陆续完工转固带来计提折旧增加，同时创新药等研发投入加大使得研发费用等期间费用同比 有所增加。 1月31日，博瑞医药发布的业绩预告显示，预计2025年年度实现归属于母公司所有者的净利润4130万元 到6190万元，同比减少67.28%到78.17%。预计2025年年度实现归属于母公司所有者的扣除非经常性损 益的净利润430万元到2490万元，同比减少86.21%到97.62%。 此前，东方金诚受托对博瑞医药及其发行的"2021年博瑞生物医药(苏州)股份有限公司向不特定对象发 行可转换公司债券"(以下简称"博瑞转债")进行了信用评级。2025年5月27日，东方金诚对博瑞医药主体 及"博瑞转债"进行了定期跟踪评级，维持博瑞医药主体 ...

Group 1 - Zhejiang Mining Co., Ltd. plans to acquire 100% equity of Alaigyr Company in Kazakhstan for approximately 406 million RMB, which includes a cash payment of about 4.8853 million RMB and shareholder loans amounting to approximately 40.1564 million RMB [1] - The acquisition price will be finalized based on subsequent audits, evaluations, and the financial condition of the target company's balance sheet on the closing date [1] - Alaigyr Company holds a core asset, which is a lead-silver mine located in the Karaganda region of Kazakhstan [1] Group 2 - Shandong Zhanggu expects a net profit of 72 million to 80 million RMB for the fiscal year 2025, representing a year-on-year growth of 0.65% to 11.83% [2] - Various convertible bonds are listed with their respective details, including current prices, redemption prices, last trading dates, and conversion values [4][6] - Hengyi Petrochemical's controlling shareholder has raised the upper limit of its share buyback plan to 15 RMB [8]

Group 1 - The company, Borui Biopharmaceutical (Suzhou) Co., Ltd., will begin paying interest on its convertible bonds, "Borui Convertible Bonds," on January 5, 2026, for the period from January 4, 2025, to January 3, 2026 [2][4] - The total amount of convertible bonds issued is 46.5 million yuan, with a face value of 100 yuan per bond, and the bonds have a six-year term from January 4, 2022, to January 3, 2028 [2][16] - The interest rates for the bonds are structured to increase over the years, starting at 0.4% in the first year and reaching 3% in the sixth year [2][4] Group 2 - The interest payment for the fourth year will be at a rate of 1.5%, resulting in a payment of 15 yuan per bond (tax included) [8] - The bondholders will be registered as of December 31, 2025, and the interest will be paid on January 5, 2026 [9][10] - The company has established a process for interest payment through a designated clearing company, which will handle the distribution of interest to bondholders [10] Group 3 - The convertible bonds can be converted into shares from July 11, 2022, to January 3, 2028, with an initial conversion price of 35.68 yuan per share, which has been adjusted to 34.74 yuan per share [3][17] - The company has outlined redemption terms for the bonds, including conditions under which the company may redeem the bonds at 115% of the face value [19][20] - The company has indicated that the redemption clause may be triggered if the stock price meets certain conditions, specifically if it remains above 130% of the conversion price for a specified number of trading days [20][21]

Group 1 - The company, Borui Pharmaceutical (688166.SH), announced that the convertible bonds issued on January 4, 2022, will start paying interest on January 5, 2026, due to January 4 being a non-trading day [1] - This interest payment marks the fourth year of interest for the "Borui Convertible Bonds," with the interest period from January 4, 2025, to January 3, 2026 [1] - The coupon rate for this interest year is set at 1.5% (tax included), meaning each unit of "Borui Convertible Bonds" (with a face value of 1,000 RMB) will yield an interest payment of 15 RMB (tax included) [1]

Core Viewpoint - The company, Borui Pharmaceutical (688166.SH), announced that the interest payment for its convertible bonds issued on January 4, 2022, will commence on January 5, 2026, due to January 4, 2026, being a non-trading day [1] Group 1 - The interest payment marks the fourth year of interest for the "Borui Convertible Bonds" [1] - The interest accrual period is from January 4, 2025, to January 3, 2026 [1] - The coupon rate for this interest year is set at 1.5% (tax included), resulting in an interest payment of 15 RMB (tax included) for each bond with a face value of 1,000 RMB [1]

Core Viewpoint - The China Convertible Bond Index rose by 0.39% on December 19, reaching 485.31 points, indicating a positive trend in the convertible bond market [1][2] Group 1: Market Performance - The China Convertible Bond Index closed at 485.31 points after a morning increase of 0.39% [1][2] - Notable gainers included: - Jia Mei Convertible Bond, which increased by 16.34% - Hua Ti Convertible Bond, which rose by 13.62% - Hui Cheng Convertible Bond, which saw a rise of 10.14% [1][2] - Conversely, the following bonds experienced declines: - Bo Rui Convertible Bond, which fell by 9.47% - Jin Zhong Convertible Bond, which decreased by 4.91% - Rui Da Convertible Bond, which dropped by 2.44% [1][2]

Core Viewpoint - The China Convertible Bond Index experienced a slight decline of 0.07%, closing at 482.61 points on December 15, indicating a mixed performance in the convertible bond market [1]. Group 1: Market Performance - The China Convertible Bond Index fell by 0.07% to 482.61 points [1]. - Notable gainers included Guanzhong Convertible Bond, which rose by 13.39%, Bojun Convertible Bond with a 4.48% increase, and Yake Convertible Bond, which increased by 4.22% [1]. - Conversely, Jiaze Convertible Bond decreased by 5.40%, Yingbo Convertible Bond fell by 3.86%, and Borui Convertible Bond dropped by 3.47% [1].

Core Viewpoint - The Zhongzheng Convertible Bond Index opened with a slight increase of 0.08%, reaching 477.96 points on September 16 [1] Group 1: Market Performance - The top gainers in the convertible bond market included Yuguang Convertible Bond, Borui Convertible Bond, New 23 Convertible Bond, Songsheng Convertible Bond, and Yinlun Convertible Bond, with increases of 6.74%, 4.28%, 3.05%, 1.98%, and 1.97% respectively [1] - The largest decliners were Haitai Convertible Bond, Jiuzhou Turn 2, Luokai Convertible Bond, Aofei Convertible Bond, and Yiwei Convertible Bond, with decreases of 5.02%, 3.76%, 1.71%, 1.42%, and 1.40% respectively [1]

Core Viewpoint - The company, Borui Pharmaceutical, announced that it will not exercise the early redemption rights for its convertible bonds, known as "Borui Convertible Bonds," during the upcoming board meeting scheduled for September 11, 2025 [2]. Group 1 - The fourth session of the company's eleventh board meeting will take place on September 11, 2025 [2]. - The company has decided not to redeem the "Borui Convertible Bonds" early [2].

Group 1 - The subscription result for CapitaLand Commercial REITs (508091) shows a total subscription amount of 146.5 billion [1] - The subscription for the new stock Shichang Co., which was listed on the Beijing Stock Exchange, reached 649.6 billion on the same day [1] - The total idle funds for new stock subscriptions amount to approximately 800 billion, calculated as 146.5 billion + 649.6 billion [1] Group 2 - Shareholders of Jinpu Garden plan to reduce their holdings by no more than 4.58% of the company's shares [1] - The Bo Rui convertible bond will not be forcibly redeemed [2] - The Fangyuan convertible bond will not undergo a downward adjustment [2] Group 3 - The listing of CICC Vipshop Outlet REIT (508082) has occurred [1]